113 related articles for article (PubMed ID: 15731017)
1. Outpatient therapeutic 131I for thyroid cancer.
Panzegrau B; Gordon L; Goudy GH
J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
[TBL] [Abstract][Full Text] [Related]
2. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
3. NRC absorbed dose reconstruction for family member of 131I therapy patient: case study and commentary.
Marcus CS; Siegel JA
J Nucl Med; 2004 Apr; 45(4):13N-6N, 37N. PubMed ID: 15073236
[No Abstract] [Full Text] [Related]
4. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
Coover LR; Silberstein EB; Kuhn PJ; Graves MW
J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
[TBL] [Abstract][Full Text] [Related]
5. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.
Willegaignon J; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Clin Nucl Med; 2011 Jun; 36(6):440-5. PubMed ID: 21552020
[TBL] [Abstract][Full Text] [Related]
6. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
Parthasarathy KL; Crawford ES
J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
[TBL] [Abstract][Full Text] [Related]
8. 131I effective half-life (Teff) for patients with thyroid cancer.
Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
[TBL] [Abstract][Full Text] [Related]
9. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
[TBL] [Abstract][Full Text] [Related]
10. Radiation safety considerations for post-iodine-131 thyroid cancer therapy.
Culver CM; Dworkin HJ
J Nucl Med; 1992 Jul; 33(7):1402-5. PubMed ID: 1613585
[TBL] [Abstract][Full Text] [Related]
11. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
12. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
13. [Exposure of relatives of patients after stationary radioiodine therapy by inhalation of 131I in their homes].
Wellner U; Eschner W; Hillger HW; Schicha H
Nuklearmedizin; 1998 May; 37(3):113-9. PubMed ID: 9604232
[TBL] [Abstract][Full Text] [Related]
14. Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given.
Pace-Asciak PZ; Payne RJ; Eski SJ; Walfish P; Damani M; Freeman JL
Arch Otolaryngol Head Neck Surg; 2007 Sep; 133(9):870-3. PubMed ID: 17875852
[TBL] [Abstract][Full Text] [Related]
15. 131I effective half-life and dosimetry in thyroid cancer patients.
Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
[TBL] [Abstract][Full Text] [Related]
16. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study.
Walter MA; Turtschi CP; Schindler C; Minnig P; Müller-Brand J; Müller B
J Nucl Med; 2007 Oct; 48(10):1620-5. PubMed ID: 17873131
[TBL] [Abstract][Full Text] [Related]
17. Neutron activation of patients following boron neutron capture therapy of brain tumors at the high flux reactor (HFR) Petten (EORTC Trials 11961 and 11011).
Wittig A; Moss RL; Stecher-Rasmussen F; Appelman K; Rassow J; Roca A; Sauerwein W
Strahlenther Onkol; 2005 Dec; 181(12):774-82. PubMed ID: 16362787
[TBL] [Abstract][Full Text] [Related]
18. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
19. Risk of thyroid cancer after exposure to 131I in childhood.
Cardis E; Kesminiene A; Ivanov V; Malakhova I; Shibata Y; Khrouch V; Drozdovitch V; Maceika E; Zvonova I; Vlassov O; Bouville A; Goulko G; Hoshi M; Abrosimov A; Anoshko J; Astakhova L; Chekin S; Demidchik E; Galanti R; Ito M; Korobova E; Lushnikov E; Maksioutov M; Masyakin V; Nerovnia A; Parshin V; Parshkov E; Piliptsevich N; Pinchera A; Polyakov S; Shabeka N; Suonio E; Tenet V; Tsyb A; Yamashita S; Williams D
J Natl Cancer Inst; 2005 May; 97(10):724-32. PubMed ID: 15900042
[TBL] [Abstract][Full Text] [Related]
20. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
Marriott CJ; Webber CE; Gulenchyn KY
Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
